Ultragenyx Pharmaceutical, Inc. (RARE)
16.13
-0.28
(-1.71%)
USD |
NASDAQ |
Nov 10, 16:00
16.13
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash from Operations (Annual) : -466.00M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -466.00M |
| December 31, 2024 | -414.19M |
| December 31, 2023 | -474.81M |
| December 31, 2022 | -380.46M |
| December 31, 2021 | -338.70M |
| December 31, 2020 | -132.22M |
| December 31, 2019 | -345.38M |
| December 31, 2018 | -290.57M |
| Date | Value |
|---|---|
| December 31, 2017 | -253.84M |
| December 31, 2016 | -160.98M |
| December 31, 2015 | -105.98M |
| December 31, 2014 | -44.63M |
| December 31, 2013 | -31.20M |
| December 31, 2012 | -12.50M |
| December 31, 2011 | -5.825M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Ionis Pharmaceuticals, Inc. | -268.58M |
| AbbVie, Inc. | 19.03B |
| Krystal Biotech, Inc. | 200.86M |
| BridgeBio Pharma, Inc. | -445.91M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |